Intravitreal anti-VEGF therapy has transformed the clinical landscape for common conditions like age-related macular degeneration (ARMD) and diabetic retinopathy. However, recent evidence suggests its utility extends far beyond these primary indications. Clinicians now use these agents to manage a variety of secondary neovascular and exudative retinal disorders. This expansion offers new hope for patients with rarer or more complex ocular pathologies.

Clinical Utility of Intravitreal Anti-VEGF Therapy in Diverse Retinopathies

Beyond the established protocols for ARMD, intravitreal anti-VEGF therapy is proving effective in conditions like central serous chorioretinopathy (CSCR). While photodynamic therapy remains a staple, anti-VEGF agents help reduce subretinal fluid and macular thickness in chronic cases. Similarly, in macular telangiectasia type 2 (MacTel), these agents provide significant functional benefits, particularly when secondary neovascularization occurs.

Furthermore, pediatric ophthalmology has seen a paradigm shift. For instance, retinopathy of prematurity (ROP), especially zone 1 disease, often responds better to anti-VEGF than traditional laser therapy. This approach preserves peripheral vision and reduces the risk of severe myopia. Additionally, rare disorders like Coats' disease and retinal vasoproliferative tumors (RVPTs) benefit from the drying effect of these injections, which manage exudation effectively.

Moreover, the therapy shows promise in managing neovascularization secondary to inflammatory conditions like tubercular granuloma. It also helps stabilize vision in patients with angioid streaks or choroidal osteoma. Consequently, the role of vascular endothelial growth factor inhibition continues to grow, encompassing both vascular and non-vascular retinal disorders.

Which conditions besides ARMD benefit from anti-VEGF?

Intravitreal anti-VEGF therapy is increasingly used for central serous chorioretinopathy, retinopathy of prematurity, macular telangiectasia type 2, and Coats' disease. It is also employed in rare cases like retinal vasoproliferative tumors and tubercular granulomas.

Is anti-VEGF effective for chronic CSCR?

Yes, anti-VEGF agents can significantly decrease macular thickness and resolve subretinal fluid in chronic central serous chorioretinopathy. Although photodynamic therapy is often preferred, anti-VEGF is a viable adjunctive or alternative option.

How does anti-VEGF help in pediatric retinal diseases?

In diseases like ROP and Coats', anti-VEGF helps control abnormal vessel growth and exudation. This treatment is particularly useful in ROP to avoid the peripheral vision loss associated with extensive laser photocoagulation.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Singh S et al. Expanding horizons of intravitreal anti-vascular endothelial growth factor therapy in retinal diseases. Indian J Ophthalmol. 2026 May 01. doi: 10.4103/IJO.IJO_3035_25. PMID: 42060352.

Hang A et al. Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Retinal Disorders. Pharmaceutics. 2023 Aug 11;15(8):2118. doi: 10.3390/pharmaceutics15082118.

Ahmed D et al. Anti-Vascular Endothelial Growth Factor Treatment Outcomes in Macular Telangiectasia: A Systematic Review. Cureus. 2023 Sep 26;15(9):e45995. doi: 10.7759/cureus.45995.